Immunõ 2026: Where Is Cancer Immunotherapy Heading Next?
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy
Highlights from SIOP 2026
WHO Flags Six Essential Childhood Cancer Medicines Facing Critical Access Gaps
Patrizia Giannatempo: A New Perioperative Era in MIBC
STAS in Stage I Lung Adenocarcinoma Is More Than a Histologic Finding: Multi-Omic Profiling Reveals an Aggressive Molecular Phenotype
Robin Zon: ASCO Highlights Medicaid Policy Changes and Continuity of Cancer Care
Atezolizumab Plus Gemcitabine/Cisplatin in Metastatic Urothelial Cancer
